On April 16, 2026, Aimed Alliance sent a letter to New Jersey Assemblywoman Lisa Swain, Chair of the Assembly Appropriations Committee, urging the Committee to strengthen Assembly Bill 1502 to ensure that PBM reform delivers meaningful benefits to patients.
While commending New Jersey for its leadership in advancing PBM oversight, the letter explains that additional amendments are necessary, including requiring the 100 percent pass‑through of drug rebates to benefit consumers, strengthening formulary placement standards, banning spread pricing, expanding formulary transparency requirements, and establishing enforceable oversight mechanisms. The letter emphasizes that, despite the bill’s positive intent, stronger safeguards are needed to promote patient affordability, and PBM transparency and accountability.
Read the NJ PBM AB 1502
Last Updated on April 22, 2026 by Aimed Alliance
